10-Q Filing

MERCK & CO., INC. CIK: 310158 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001628280-23-015990`
Period End Date	20230331
Filing Date	20230505
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	mrk-20230331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 78 Income Statement 28 Cash Flow Statement 60 Comprehensive Income 12

Balance Sheet 78 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$76.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$72.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.28B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.94B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.26B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.98B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.69B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.71B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$498.00M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$680.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$9.45B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$10.41B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$5.86B	USD	Point-in-time
Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$5.91B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$7.17B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$6.74B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$33.40B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$35.72B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.01B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.29B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$21.76B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$21.42B	USD	Point-in-time
Goodwill	`Goodwill`	$21.21B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$20.27B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$19.86B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$10.28B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$9.53B	USD	Point-in-time
Total Assets	`Assets`	$109.16B	USD	Point-in-time
Total Assets	`Assets`	$107.80B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.95B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.67B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.26B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.68B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$13.00B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.16B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.99B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.87B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.91B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$24.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$23.13B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.75B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.07B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.44B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.32B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.24B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.47B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.38B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$62.04B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.08B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.88B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.77B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.48B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$103.41B	USD	Point-in-time
Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.49B	USD	Point-in-time
Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.58B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$46.83B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$45.99B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$71.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$67.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.91B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.95B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$109.16B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$107.80B	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$14.49B	USD	1 Quarter
Sales	`Revenues`	$15.90B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$5.38B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.93B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.32B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.48B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.28B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.58B	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$67.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$53.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-89.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-708.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.84B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$11.04B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.86B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.65B	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$554.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$825.00M	USD	1 Quarter
Net Income	`ProfitLoss`	$2.83B	USD	1 Quarter
Net Income	`ProfitLoss`	$4.31B	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$-3.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$4.00M	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.31B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.70	USD	1 Quarter
Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.11	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.11	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.70	USD	1 Quarter

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$58.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$71.00M	USD	Point-in-time
Net income	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	1 Quarter
Net income	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$4.31B	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$699.00M	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$543.00M	USD	1 Quarter
Depreciation	`Depreciation`	$448.00M	USD	1 Quarter
Depreciation	`Depreciation`	$421.00M	USD	1 Quarter
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$450.00M	USD	1 Quarter
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-708.00M	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-338.00M	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-277.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$120.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$145.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-143.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$197.00M	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.30B	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.89B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$1.34B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$4.76B	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.01B	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$984.00M	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$372.00M	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$562.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$500.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$1.00M	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-37.00M	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-182.00M	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.36B	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.17B	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$1.25B	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$1.00M	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$149.00M	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.85B	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.75B	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$30.00M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$12.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-103.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-81.00M	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.05B	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-3.09B	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-55.00M	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$87.00M	USD	1 Quarter
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.99B	USD	1 Quarter
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$447.00M	USD	1 Quarter
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.61B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.61B	USD	Point-in-time

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.31B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$63.00M	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-133.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$50.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-32.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$68.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-35.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$60.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-115.00M	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.71B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.37B	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.